APA (7th ed.) Citation

Korhonen, P., Zuber, E., Branson, M., Hollaender, N., Yateman, N., Katiskalahti, T., . . . Haas, T. (2012). Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma. Journal of Biopharmaceutical Statistics, 22(6), 1258. https://doi.org/10.1080/10543406.2011.592233

Chicago Style (17th ed.) Citation

Korhonen, P., E. Zuber, M. Branson, N. Hollaender, N. Yateman, T. Katiskalahti, D. Lebwohl, and T. Haas. "Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma." Journal of Biopharmaceutical Statistics 22, no. 6 (2012): 1258. https://doi.org/10.1080/10543406.2011.592233.

MLA (9th ed.) Citation

Korhonen, P., et al. "Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma." Journal of Biopharmaceutical Statistics, vol. 22, no. 6, 2012, p. 1258, https://doi.org/10.1080/10543406.2011.592233.